Skip to main content

Table 3 Results of regression models: Association of AATD and AT with annual direct and indirect costs

From: Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients

  Direct costs Indirect costs
Costs   Total direct costs Outpatient costs Inpatient costs Medication costs Other costs HC FC
Group A Ref. Ref. Ref. Ref. Ref. Ref. Ref.
B1 0.95 (0.80 – 1.12) 2.73 (2.35 – 3.17) 0.65 (0.45 – 0.94) 0.90 (0.79 – 1.03) 1.14 (0.81 – 1.61) 1.05 (0.79 – 1.39) 0.94 (0.66 – 1.35)
B2 0.80 (0.57 – 1.13) 1.13 (0.84 – 1.51) 0.79 (0.39 – 1.63) 0.72 (0.56 – 0.93) 1.23 (0.65 – 2.34) 0.67 (0.38 – 1.18) 1.18 (0.67 – 2.08)
  1. A = COPD patients without Alpha-1-antitrypsin deficiency (AATD), B1 = COPD patients with AATD and augmentation therapy (AT), B2 = COPD patients with AATD but without AT
  2. Indirect costs only include patients < 65 years of age
  3. Significant estimates on a level of p < .05 are printed bold
  4. Other costs include Physiotherapist and Rehabilitation costs
  5. HC Human capital approach, FC Friction costs approach
  6. Total direct costs and medication costs do not include AT costs of approximately €72,000